Picture of Thermogenesis Holdings logo

THMO — Thermogenesis Holdings News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyHighly SpeculativeMicro Cap

ThermoGenesis: H.C. Wainwright cuts PT on Q3 rev dip; shares fall

** Shares of cell-based therapy company  THMO.O  fall 7% to
a two-week low of $2.14
    ** H.C. Wainwright cuts PT to $8.50 from $9.50 after THMO on
Thursday reported a 42% plunge in Q3 rev as demand for its cord
blood banking products was hurt by the COVID-19 pandemic
 urn:newsml:reuters.com:*:nPn2gwDrZa
    ** Brokerage says despite recent positive news on vaccine
development, it may be 12-18 months before an effective vaccine
becomes widely available; lowers Q4 rev estimate to $2.6 mln
from $6.1 mln
    ** Expects the cord blood banking industry to recover over
2021 and 2022 as the pandemic subsides
    ** With the growing prominence of cell therapies, there
would be growing demand for THMO's cell processing products as
well - brokerage
    ** Believes cell processing products and services remain the
most important long-term growth drivers for co
    ** Up to Thursday's close, stock down 47.7% this year

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))

Recent news on Thermogenesis Holdings

See all news